17354-63-1

Basic information

• Product Name: 1-(P-METHOXYPHENYL)2-NITROPROPENE
• Synonyms: 1-(P-METHOXYPHENYL)2-NITROPROPENE;p-(2-nitropropenyl)anisole;1-(4-METHOXYPHENYL)-2-NITROPROPENE, >95%;2-Nitro-1-(4-methoxyphenyl)-1-propene;1-Methoxy-4-(2-nitro-1-propenyl)benzene;4-Methoxy-β-methyl-β-nitrostyrene;Ai3-63172;Benzene, 1-methoxy-4-(2-nitro-1-propenyl)-
• CAS NO: 17354-63-1
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.2
• EINECS: 241-381-5
• Product Categories: API intermediates
• Mol File: 17354-63-1.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 321.7°Cat760mmHg
• Flash Point: 147.4°C
• Appearance: /
• Density: 1.156g/cm³
• Vapor Pressure: 0.000551mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 1-(P-METHOXYPHENYL)2-NITROPROPENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(P-METHOXYPHENYL)2-NITROPROPENE(17354-63-1)
• EPA Substance Registry System: 1-(P-METHOXYPHENYL)2-NITROPROPENE(17354-63-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 17354-63-1(Hazardous Substances Data)

Usage

Uses

1-(p-Methoxyphenyl)-2-nitro-1-propene is an intermediate in the synthesis of 4-Methoxyamphetamine Hydrochloride (M261015), the HCl salt of 4-Methoxyamphetamine which is a designer drug belonging to the amphetamine class and releases 5-hydroxytryptamine in brain tissue.

InChI:InChI=1/C10H11NO3/c1-8(11(12)13)7-9-3-5-10(14-2)6-4-9/h3-7H,1-2H3

Upstream product

• 79-24-3 Nitroethane 
• 123-11-5 4-methoxy-benzaldehyde 
• 2393-23-9 4-methoxy-benzylamine 
• 148527-33-7 2-nitro-1-hydroxy-1-(4-methoxy-phenyl)-propane 
• 135711-43-2 Butyl-[1-(4-methoxy-phenyl)-2-nitro-propyl]-amine 
• 148527-35-9 1-(4-methoxyphenyl)-2-nitropropyl acetate 
• 918-37-6 hexanitroethane 
• 104-46-1 anethole 
• 509-14-8 tetranitromethane 
• 110-86-1 pyridine 
• 60-29-7 diethyl ether 
• 67-64-1 acetone 

Downstream Products

• 142865-84-7 (4RS,5SR,6SR)-4-(4-methyloxyphenyl)-3-methyl-4a,5,6,7,8,8a-hexahydro-4H-benzo[e]-1,2-oxazine N-oxide 
• 95838-70-3 4-(4-Methoxyphenyl)-2,5-dimethyl-3-pyrrolcarbonsaeure-tert-butylester 
• 98450-45-4 1-<2-Hydroxy-1-(methoxycarbonyl)-1-propenyl>-4-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolcarbonsaeure-methylester 
• 98450-67-0 1-<1-Chlor-1-(methoxycarbonyl)-2-oxopropyl>-4-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolcarbonsaeure-methylester 
• 188716-80-5 2-hydroxymethyl-4-methyl-3-(4-methoxyphenyl)-1H-pyrrole 
• 124901-18-4 2,7,12,17-tetramethyl-3,8,13,180tetra(p-methoxyphenyl)porphiryn 
• 1519057-34-1 3-(4-methoxyphenyl)-2,6,6-trimethyl-1-phenyl-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1519057-48-7 1-(4-chlorophenyl)-3-(4-methoxyphenyl)-2,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1519057-56-7 3-(4-methoxyphenyl)-2,6,6-trimethyl-1-(o-tolyl)-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1519057-92-1 3-(4-methoxyphenyl)-2-methyl-1-(o-tolyl)-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1519057-68-1 1-cyclopropyl-3-(4-methoxyphenyl)-2,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1519057-84-1 1-(2-chlorophenyl)-3-(4-methoxyphenyl)-2-methyl-1,5,6,7-tetrahydro-4H-indol-4-one 
• 1215288-76-8 1-acetylamino-2-bromo-1-(4-methoxyphenyl)-2-nitropropane 
• 1042149-14-3 2-methyl-3-(4-methoxyphenyl)-6,7-dihydro-5H-benzofuran-4-one 

Relevant articles and documents

Reactions of 1-Aryl-1,2-dibromo-2-nitropropanes with 2-Nitro-2-propyl Anion in DMSO

-

A diversity-oriented synthesis of polyheterocycles: Via the cyclocondensation of azomethine imine

Pd-Catalyzed sequential reactions to afford skeletally diverse molecules are described. The reaction involved azomethine imine formation and a cyclocondensation reaction as individual steps. The methodology provides excellent regio- and stereocontrol. Skeletal diversity was ensured by changing the electrophilic counterpart of azomethine imine. Due to its broader diversity and complexity, the DOS methodology is likely to benefit drug discovery and development in the future.

METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY

Provided herein are methods and compositions for selective and targeted cancer therapy, in particular certain benzothiophenes, benzothiazoles, oxalamides, N-acyl ureas and chromones, and their use in selectively treating certain adenocarcinomas. In some embodiments, the selective toxicity of the compounds may be mediated through SCD1 and/or CYP450 such as CYP4F11.